Spontaneous and drug-induced movement disorders in schizophrenia

Acta Psychiatrica Scandinavica

Volumn 94, Issue SUPPL.S389, 1996, Pages 12-17

  Kopala, L C ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anticholinergic medication: treatment strategies; Compliance; Extrapyramidal side effects, clinical experience; First episode schizophrenia: Risperidone; Quality of life

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RISPERIDONE;

CHRONIC DISEASE; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; HUMAN; NEUROLOGIC EXAMINATION; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; CONFERENCE PAPER; CONSTIPATION; EXTRAPYRAMIDAL SYNDROME; MEMORY; MOTOR DYSFUNCTION;

ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HUMANS; NEUROLOGIC EXAMINATION; QUALITY OF LIFE; RECURRENCE; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0030333717     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1996.tb05943.x     Document Type: Article

References (32)

1. Chatterjee A, Chakos M, Koreen A et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995: 152: 1724-1729.
2. Caliguri MP, Lohr JB, Jeste DV. Parkinsonism in neuro-leptic-nai've schizophrenic patients. Am J Psychiatry 1993: 150: 1343-1348.
3. Kane JM, Woerner M, Lebberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988: 8 (Suppl. 4): 52-56.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994: 151: 1825-1835.
5. Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risper-idone and haloperidol in the treatment of chronic schizo-phrenic patients. J Clin Psychopharmacol 1993: 13: 25-40.
6. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995: 166: 712-726.
7. Gupta S, Andreasen NC, Arndt S et al. Neurological soft signs in neuroleptic-nai've and neuroleptic-treated schizo-phrenic patients and in normal comparison subjects. Am J Psychiatry 1995: 152: 191-196.
8. Carlsson A. Does dopamine play a role in schizophrenia?. Psychol Med 1977: 7: 583-597.
9. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizo-phrenia: role of 5-HT2 receptor and aj-adrenoceptor antag-onism. J Clin Psychopharmacol 1995: 15 (Suppl. 1): 11S-18S.
10. Beerpoot LJ, Lipska BK, Weinberger DR. Neurobiology of treatment-resistant schizophrenia: new insights and new models. Eur Neuropsychopharmacol 1996: 6: 27-34.
11. Aguilar EJ, Matcheri SK, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994: 151: 1819-1821.
12. McEvoy J, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991: 48: 739-745.
13. Davis JM, Andriukutis S. The natural course of schizo-phrenia and effective maintenance therapy. J Clin Psychopharmacol 1986: 6 (Suppl. 1): 2-10.
14. van Putten T. Why do schizophrenic patients refuse to take their drugs?. Arch Gen Psychiatry 1974: 31: 67-72.
15. Haase HJ. Extrapyramidal modifications of fine move-ments - a 'conditio sine qua nori of fundamental therapeutic action of neuroleptic drugs. Rev Canada Biol 1961: 20: 425-449.
16. Johnstone EC, Crow TJ, Ferrer IN et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983: 13: 513-527.
17. Tune LE, Strausse ME, Lew MF et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982: 139: 1460-1462.
18. Calev A. Anticholinergic drugs and memory. Br J Psychiatry 1983: 143: 422 423.
19. Baker LA, Cheng LY, Amamra IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983: 143: 584-590.
20. Capstick N. Long term fluphenazine decanoate. Maintenance dosage requirements of chronic schizophrenic patients. Acta Psychiatr Scand 1980: 61: 256-262.
21. Jolley AG, Hirsch SR, Morrison E et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizo-phrenic outpatients: clinical and social outcome at two years. Br Med J 1990: 301: 837-842.
22. Herz MI, Glazer WM, Mostert MA et al. Intermittent vs. maintenance treatment in schizophrenia: two-year results. Arch Gen Psychiatry 1991: 48: 333-339.
23. Meltzer HY. The mechanism of action of novel antipsych-otic drugs. Schizophr Bull 1991: 17: 263-287.
24. Leysen JH, Janssen PMF, Megens AAHP, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile and phar-macologic activity. J Clin Psychopharmacol 1994: 55 (Suppl. 5): 5-12.
25. Haase HJ, Janssen PAJ. The action of neuroleptic drugs. Chicago: Year Book Publishers, 1965.
26. McEvoy J. Dosing issues: target symptoms and dose response. Psychiatr Ann 1995: 25: 297-300.
27. Emsley RA, McCreadie R, Livingston M, de Smedt G, Lemmens P. Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind, multicentre study. Poster presentation at Campaign on Schizophrenia Conference 'Critical Issues in Treatment', Florence, March 1995.
28. Kopala LC, Fredrikson D, Good KP, Honer WG. Symptoms in neuroleptic-nai've first-episode schizophrenia: response to risperidone. Biol Psychiatry 1996: 39: 296-298.
29. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993: 162: 80 86.
30. Lindstrom E, von Knorring L. Changes in single symp-toms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 1994: 27: 108-113.
31. Randolph C, Goldberg TE, Weinberger DR. The neuro-psychology of schizophrenia. In: Heilman KM, Valensteine E, eds. Clinical neuropsychology, 3rd edn. Oxford: Oxford University Press, 1993: 499-522.
32. Loebel AD, Lieberman JA, Alir JMJ, MayerhoffDI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992: 149: 1183-1188.